Loading…
The Centre has sanctioned a ₹1,000 crore grant-in-aid for Common Infrastructure Facilities (CIF) at the Bulk Drug Park being developed at Haroli, Una district, Himachal Pradesh, under the Scheme for Promotion of Bulk Drug Parks.
As of 30 June 2026, Himachal Pradesh had utilised ₹116 crore of the Central grant; the park's total project cost is ₹1,923 crore, with expected direct employment of 15,000-20,000 and investment of ₹8,000-10,000 crore.
The scheme's tenure has been extended up to FY2026-27 owing to delays, chiefly the environmental clearance, which was granted only on 25 September 2025.
Build shared infrastructure to cut manufacturing costs and reduce API import dependence
Key: 3 parks approved (HP, Gujarat, AP); ₹3,000 crore national outlay (2020); 70% CIF funding generally, 90% for hilly states
Incentivise domestic manufacture of critical APIs, Key Starting Materials and Drug Intermediates
Key: ₹6,940 crore outlay; had generated cumulative sales of about ₹2,720 crore, including exports of ₹527.96 crore, as of FY2022-23
State Implementing Agency for the Haroli Bulk Drug Park; receives and utilises the Central grant-in-aid
Complements the Bulk Drug Parks scheme — parks build shared infrastructure while the PLI scheme incentivises production of the same critical APIs, both aimed at cutting India's import dependence on countries such as China.
GS Paper 3 > Industry > Pharmaceutical Sector, Industrial Policy
Recurring Parliament reply topic; scheme progress reviewed periodically
Shared infrastructure — effluent treatment, power, water, logistics — built at a Bulk Drug Park to lower individual manufacturers' capital and operating costs.
A wastewater treatment approach in which no liquid waste leaves the plant boundary; all effluent is treated and reused.